RxDoctor Payments Data

Muhammad Nawaz, MD

Internal Medicine · Wesley Chapel, FLNPI 1083656201

Payments from drug & device makers

$5,483in general payments, 2019–2025

Across 242 payments — averaging $22.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$918
  • AstraZeneca$619
  • GSK$592
  • Lilly USA, LLC$447
  • Boehringer Ingelheim$444
  • Johnson & Johnson$339
  • plus $2K from 22 others

What the payments were for

  • Speaking & faculty fees$3005%
  • Food & beverage$5,18395%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,483 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$71,445
Medicare patients
125
Services billed
859

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin185$232,506
EliquisApixaban104$106,925
RybelsusSemaglutide48$83,281
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$57,909
FarxigaDapagliflozin Propanediol39$36,838
OzempicSemaglutide25$32,081
XareltoRivaroxaban16$18,497
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$16,662
Tresiba Flextouch U-100Insulin Degludec11$6,437
Ranolazine ErRanolazine15$4,685
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$4,411
Atorvastatin Calcium456$3,946
Ezetimibe182$3,151
Losartan Potassium339$2,484
ShingrixVaricella-Zoster Ge/As01b/Pf11$2,410

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$444$232,506185 claims
Novo NordiskRybelsus, Ozempic$918$115,36273 claims
PfizerEliquis$234$106,925104 claims
GSKTrelegy Ellipta, Shingrix$592$60,31855 claims
AstraZenecaFarxiga, Breztri Aerosphere$619$53,50052 claims
Johnson & JohnsonXarelto$339$18,49716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Wesley Chapel

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →